Table 4 Summary of primary outcome results (Time to stable INR, supra = therapeutic INR, sub-terapeutic INRs, vitamin K given, and serious adverse events)

5 mg v 10 mg

   Harrison

Crowther

INR 2.0-3.0 for 2 consecutive days & not >3.0;

p < .003

10 mg (24%) v 5 mg (66%)

RR 2.22 (95% CI 1.3-3.7)

Kovacs

   Quiroz

*taken from the published graph

^δincludes discharged with INR in-range from (Ann Int Med Vol 127, 4, pg 133)

** in-range by day 5

5 mg vs. other doses

   Ageno

INR > 2.6

5 mg (42%)

2.5 mg (26%)

   Shine

P = .007

P = .007

^δINR within range on or before day 6

^ψ completers only

Age trials

   Roberts

INR 2.0 - 3.0 for 2 consecutive days

Age v Fennerty;

p = 0.003

INR >4.5

Mean days in range (SD)

   Gedge

P = .03

Age

3.0 (1.3)

p = 0.03

P = .03

New Fennerty

2.7 (1.3)

p = 0.03

INR >4.5

Mean days in range (SD)

P = .003

Age

2.9 (1.1)

p = 0.04

P = .003

New Fennerty

2.4 (1.3)

p = 0.04

*taken from the published graph

^Φ author correspondence

^{^} 1 (age not stated)

Genotyping

   Hillman

% time INR in range

5 mg 42%

Model 42%

   Anderson

average % of INR outside range

10 mg 33%

Model 31%

% time INR in range

   Caraco

5 mg 25%

Model 45%

*taken from the published graph